SIGNA Artist

The SIGNA Artist is a whole-body magnetic resonance diagnostic device designed for high-resolution imaging across a wide range of anatomical regions, now enhanced with the AIR Recon DL software feature. This deep learning-based image reconstruction technology improves image quality through increased signal-to-noise ratio and sharpness, and offers the potential for reduced scan times while maintaining diagnostic efficacy.

The SIGNA Artist system is a whole-body magnetic resonance scanner designed to produce high-resolution images with a high signal-to-noise ratio and facilitate short scan times. It utilizes a superconducting magnet and a data acquisition system supporting up to 128 independent receive channels, employing time-varying magnetic fields and RF transmissions to generate images in various anatomical planes using diverse pulse sequences and reconstruction algorithms. The system is indicated for diagnostic imaging of the entire body, including structures like the head, neck, spine, breast, heart, abdomen, pelvis, joints, prostate, blood vessels, and musculoskeletal regions, with the potential use of contrast agents. This particular iteration of the SIGNA Artist 1.5T MR system incorporates the AIR Recon DL software feature, a deep learning-based reconstruction technology previously utilized in GE Healthcare's 3T SIGNA Premier system. The AIR Recon DL feature is engineered to enhance image quality by increasing the signal-to-noise ratio (SNR) and improving image sharpness, offering operators the ability to adjust the level of image noise reduction. Non-clinical performance testing demonstrated these improvements, confirming that the feature maintains low contrast detectability and has minimal impact on noise spectral content, average signal intensity, or the appearance of motion artifacts. Notably, AIR Recon DL was shown to maintain image SNR and sharpness even with reduced scan times. Clinical evaluations involving in vivo images and radiologist assessments further substantiated these benefits, indicating that AIR Recon DL provides images of equivalent or superior quality, preserves lesion conspicuity, and was generally preferred by radiologists for clinical use across a variety of anatomies, pulse sequences, and in scans involving pathology or exogenous contrast agents.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AIR Recon DL algorithm specifically differentiate between noise and fine anatomical detail, particularly in low-contrast regions or complex textures?; What is the quantitative impact of AIR Recon DL on scan time reduction across various anatomical regions, pulse sequences, and patient body habitus while maintaining or improving diagnostic image quality?; Are there specific patient populations, pathological conditions, or implant scenarios where the benefits of AIR Recon DL are most pronounced or, conversely, where its performance might be suboptimal or introduce artifacts?; How does the operator-selectable "level of image noise reduction" in AIR Recon DL correlate with objective image quality metrics (e.g., CNR, spatial resolution) and subjective diagnostic confidence across different clinical applications?; Beyond the reported improvements in SNR and sharpness, does AIR Recon DL introduce any subtle image texture alterations or smoothing effects that could potentially mimic or obscure early-stage pathology, especially for radiologists less familiar with deep learning-reconstructed images?